Civica announced today that it plans to launch an affordable long-acting insulin in pre-filled pens starting in January 2026.
The company plans to launch insulin glargine-yfgn in pre-filled pens at the lowest list price in the current long-acting insulin market. It intends to make the offering available in the U.S. beginning on Jan. 1, 2026.
“Civica will provide insulin glargine at a single low, transparent price, without the hidden rebates and unfair markups that harm consumers,” said Ned McCoy, President and CEO of Civica. “Our insulin initiative aligns with our mission of doing what is in the best interest of patients.”
The company plans to distribute the insulin to pharmacies at $45 per box of five pens. It considers this a significant discount to current prices in many cases. Civica recommends that pharmacies and health plans set a maximum recommended price for consumers of no more than $55.
According to Civica, the stable, transparent price contrasts with copay assistance programs offered by other manufacturers. The company says those require patients to register for access to programs that can change at any time.
Insulin glargine-yfgn improves glycemic control in adult and pediatric patients with diabetes. Civica said it tapped Biocon Biologics to manufacture its product under existing U.S. market approval.
“Biocon Biologics’ partnership with Civica to launch Insulin glargine reflects our shared commitment to tackling some of America’s most urgent healthcare challenges—notably, ensuring access to affordable medicines for those who need them the most,” said Shreehas Tambe, CEO and managing director, Biocon Biologics. “This partnership marks a meaningful step forward in expanding access to essential insulins for patients across the United States.”
